NCT03020745 - A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

January 28, 2019

Study Completion Date

November 6, 2019

Conditions

Hepatitis B

Interventions

DRUG

GSK3389404

GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

DRUG

Placebo

Placebo is available as a Clear colorless solution.

Trial Locations (21)

1229

GSK Investigational Site, Makati City

3080

GSK Investigational Site, Seoul

6000

GSK Investigational Site, Cebu

15355

GSK Investigational Site, Gyeonggi-do

41944

GSK Investigational Site, Daegu

49241

GSK Investigational Site, Busan

100015

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

100069

GSK Investigational Site, Beijing

119074

GSK Investigational Site, Singapore

169608

GSK Investigational Site, Singapore

200025

GSK Investigational Site, Shanghai

510150

GSK Investigational Site, Guangzhou

Unknown

GSK Investigational Site, Pokfulam

467-8602

GSK Investigational Site, Aichi

734-8551

GSK Investigational Site, Hiroshima

060-0033

GSK Investigational Site, Hokkaidou

213-8587

GSK Investigational Site, Kanagawa

105-8470

GSK Investigational Site, Tokyo

180-8610

GSK Investigational Site, Tokyo

614-735

GSK Investigational Site, Busan